Morphic to present at the canaccord genuity 43rd annual growth conference

Waltham, mass., aug. 09, 2023 (globe newswire) -- morphic therapeutic (nasdaq: morf), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that praveen tipirneni, m.d., president and chief executive officer, will take part in a fireside chat at the canaccord genuity 43rd annual growth conference on thursday, august 10, 2023 at 11:30 am et.
MORF Ratings Summary
MORF Quant Ranking